Full video transcriptClick to expand
Auto-generated transcript of @chaseveryday's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00If you're on a GLP one journey, I have huge news about maintenance that I need to share with you.
- 0:05I have been in maintenance since the beginning of April and I have been decreasing my dose.
- 0:09And that was really my only plan is to decrease until I get to a place where I still have reduced
- 0:17food noise, really good control over food choices, but no longer decreasing weight.
- 0:23I was down to 10 milligrams. Things had been holding steady until the last two weeks.
- 0:29I have decreased and lost another five. I do not want to lose anymore and this is what I realized.
- 0:36Prior to my GLP one medication, I could eat in a calorie deficit and it did not matter because my
- 0:42body was still holding on to not processing insulin and leptin and all of the things. So losing weight
- 0:50was not really an option for me prior to GLP ones. Now that I'm on the medicine, my body processes
- 0:57the way that it's supposed to. So if you're in a calorie deficit, you're going to lose weight.
- 1:03So I cannot continue to eat in a calorie deficit. It doesn't matter what dose I'm on. I don't know why
- 1:11we're not talking about that, but we've got to increase our calories once we're in maintenance.
- 1:18Maybe you all knew it. I don't know why. I guess I'm just so used to my body not working properly.
- 1:24I know I can just continue to chill here, eat the same things I do all the time and just
- 1:28decrease the medicine and it's going to all balance out. That is not accurate. So now I need to
- 1:34increase my food intake, which means I've got to start paying attention to what I eat again.
- 1:40For the last several months, I just kind of know how much protein I need to get in every day and
- 1:45I eat a lot of the same things over and over again. So that's easy. But now I've got to be more
- 1:51intentional about my food and increase my intake. I'll let you know how it goes.
GLP-1 maintenance tips on TikTok: what holds up?
Quick answer
The creator is tapering tirzepatide from a higher maintenance dose and reports unintended weight loss of approximately five pounds over two weeks despite no planned dietary changes. This pattern is consistent with continued GLP-1 mediated appetite suppression producing a sustained calorie deficit even at lower doses. Clinical management of GLP-1 maintenance typically involves balancing dose reduction with intentional caloric adjustments to achieve a weight-stable equilibrium, ideally under provider supervision.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 maintenance tips on TikTok: what holds up?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 maintenance tips on TikTok: what holds up?" from chaseveryday ✨. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is tapering tirzepatide from a higher maintenance dose and reports unintended weight loss of approximately five pounds over two weeks despite no planned dietary changes.
The reason this review is not generic is the source wording and the canonical claim label "glp1 if you were in maintenance on your glp one journey here is a." In this clip, the useful excerpt is: "If you're on a GLP one journey, I have huge news about maintenance that I need to share with you." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator is tapering tirzepatide from a higher maintenance dose and reports unintended weight loss of approximately five pounds over two weeks despite no planned dietary changes.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is tapering tirzepatide from a higher maintenance dose and reports unintended weight loss of approximately five pounds over two weeks despite no planned dietary changes. This pattern is consistent with continued GLP-1 mediated appetite suppression producing a sustained calorie deficit even at lower doses. Clinical management of GLP-1 maintenance typically involves balancing dose reduction with intentional caloric adjustments to achieve a weight-stable equilibrium, ideally under provider supervision.
- Tirzepatide acts on GIP and GLP-1 receptors to improve insulin sensitivity and reduce appetite, but does not override calorie balance: Jastreboff et al. (2022, NEJM) confirmed weight loss was driven by sustained caloric reduction.
- Unintended weight loss during GLP-1 dose tapering is a real clinical phenomenon and warrants upward calorie adjustment, not just further dose reduction.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide acts on GIP and GLP-1 receptors to improve insulin sensitivity and reduce appetite, but does not override calorie balance: Jastreboff et al. (2022, NEJM) confirmed weight loss was driven by sustained caloric reduction.
- Unintended weight loss during GLP-1 dose tapering is a real clinical phenomenon and warrants upward calorie adjustment, not just further dose reduction.
- The body defends its weight through adaptive thermogenesis and metabolic suppression even during pharmacotherapy, a mechanism the video does not address: Leibel et al. (1995, NEJM).
- Leptin resistance contributes to obesity but does not uniformly prevent weight loss in all patients, so the creator's claim that her body simply could not lose weight before medication is likely an oversimplification of her individual history.
- Rapid weight regain after GLP-1 discontinuation, documented in Davies et al. (2021, Lancet), suggests these medications support dietary behavior rather than replace it, reinforcing the creator's ultimate conclusion about intentional eating.
- Dose and caloric intake are separate, interacting levers in GLP-1 maintenance. Assuming dose reduction alone will stabilize weight without dietary adjustment is not supported by clinical evidence.
- Patients in GLP-1 maintenance should work with a provider to set an explicit calorie target rather than relying on intuitive eating or dose changes alone to achieve weight stability.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @chaseveryday actually say?
The short version: she's been tapering her tirzepatide dose since reaching her goal weight and kept losing anyway. Her explanation is that GLP-1 medication fixed her metabolic dysfunction, so now a calorie deficit actually works on her body the way it's supposed to. The fix, she says, is eating more, not adjusting the dose further.
She frames her previous inability to lose weight as her body "not processing insulin and leptin and all of the things." Now that the medication corrected that, she argues the old rules no longer apply. Her takeaway: "we've got to increase our calories once we're in maintenance." She's speaking from personal experience and explicitly recommends talking to a provider, which is worth acknowledging upfront.
Does the science back this up?
Partially, yes. The core logic, that GLP-1 receptor agonists improve insulin sensitivity and energy metabolism in ways that can make caloric restriction more effective, has real support in the literature. But her framing of why she couldn't lose weight before is oversimplified and sometimes inaccurate.
Tirzepatide acts on both GIP and GLP-1 receptors, improving insulin sensitivity and reducing appetite signaling. Research from Jastreboff et al. (2022, NEJM) showed tirzepatide produced substantial weight loss partly through reduced energy intake and improved metabolic function. The idea that correcting insulin resistance changes how the body responds to a calorie deficit is grounded in real physiology. However, the claim that she simply "couldn't lose weight" before due to insulin and leptin dysfunction is harder to validate without her full clinical history. Leptin resistance is real, but it doesn't universally prevent all weight loss in all patients. That framing is too clean.
What did they get wrong (or right)?
She got the main practical point right. If you're losing weight unintentionally during GLP-1 maintenance and you want to stabilize, you probably do need to eat more. That's not controversial. Where she goes sideways is attributing her pre-medication weight loss resistance entirely to broken insulin and leptin signaling.
The reality is more complicated. Pre-medication weight loss difficulty in people with obesity involves adaptive thermogenesis, behavioral factors, gut microbiome differences, and yes, sometimes insulin resistance, but it's rarely one clean mechanism. Leibel et al. (1995, NEJM) documented how the body actively defends its weight through metabolic adaptation, a factor she doesn't mention. She also says "it doesn't matter what dose I'm on" regarding the deficit causing loss, which is an overstatement. Dose absolutely influences appetite suppression and how aggressively the body defends fat stores. Her framing strips out that nuance.
- Correct: calorie balance still matters on GLP-1 therapy
- Correct: maintenance requires intentional calorie adjustment upward
- Oversimplified: attributing all prior weight loss resistance to insulin and leptin dysfunction
- Overstated: dose has no role in continued weight loss during maintenance
What should you actually know?
GLP-1 and dual GIP/GLP-1 medications do not suspend the laws of energy balance. They change the inputs, chiefly by reducing appetite and improving metabolic signaling, but a sustained calorie deficit will still produce weight loss regardless of the medication. That's the part she gets right, and it's genuinely underappreciated.
What makes her video worth watching is the honest confusion it captures. Many patients assume that dose reduction is the primary lever for stabilizing weight in maintenance. It is one lever, but caloric intake is another, and probably the more immediate one. Davies et al. (2021, Lancet) noted that weight regain after GLP-1 discontinuation is rapid, suggesting the medication's role is to support behavior change, not replace it. For anyone in maintenance, working with a provider to set an intentional calorie target, not just eating intuitively and hoping the dose handles the rest, is the more defensible approach. She's arriving at that conclusion herself, which is credit to her.
Bottom line
This video is mostly harmless and contains a genuinely useful insight for people in GLP-1 maintenance. The metabolic explanation she offers is rougher than it should be, and the claim that dose is irrelevant to ongoing loss is wrong. But the practical advice, eat more intentionally when you want to stop losing weight on these medications, is sound. Just don't use this video as a substitute for actual clinical guidance on dose titration.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
chaseveryday ✨ · TikTok creator
61.8K views on this video
If you were in maintenance on your GLP one journey, here is a major tip that I’ve discovered. Remember to always consult with your medical provider regarding questions about your health. ##selfcare##glp1journey##healthylife##wlslifestyle##tirzejourney##wskincareroutine##tirzepatidecompound
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide acts on gip?
Tirzepatide acts on GIP and GLP-1 receptors to improve insulin sensitivity and reduce appetite, but does not override calorie balance: Jastreboff et al. (2022, NEJM) confirmed weight loss was driven by sustained caloric reduction.
What does the video say about unintended weight loss during glp-1 dose tapering?
Unintended weight loss during GLP-1 dose tapering is a real clinical phenomenon and warrants upward calorie adjustment, not just further dose reduction.
What does the video say about the body defends its weight through adaptive thermogenesis?
The body defends its weight through adaptive thermogenesis and metabolic suppression even during pharmacotherapy, a mechanism the video does not address: Leibel et al. (1995, NEJM).
What does the video say about leptin resistance contributes to obesity?
Leptin resistance contributes to obesity but does not uniformly prevent weight loss in all patients, so the creator's claim that her body simply could not lose weight before medication is likely an oversimplification of her individual history.
What does the video say about rapid weight regain after glp-1 discontinuation, documented in davies et?
Rapid weight regain after GLP-1 discontinuation, documented in Davies et al. (2021, Lancet), suggests these medications support dietary behavior rather than replace it, reinforcing the creator's ultimate conclusion about intentional eating.
Dose and caloric intake are separate, interacting levers in GLP-1 maintenance. Assuming dose reduction alone will stabilize weight without dietary adjustment is not supported by clinical evidence?
Dose and caloric intake are separate, interacting levers in GLP-1 maintenance. Assuming dose reduction alone will stabilize weight without dietary adjustment is not supported by clinical evidence.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by chaseveryday ✨, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.